Highlights

  • Cleo Diagnostics (ASX:COV) has established US clinical testing infrastructure at Asuragen, the CLIA-certified laboratory of Bio-Techne, with inter-laboratory reproducibility studies now underway.
  • Clinical Validation of the Pre-Surgical Ovarian Cancer Test is expected to commence within the next month following receipt of test kits at the laboratory.
  • The Clinical Validation program will involve testing approximately 1,470 samples across three study populations to evaluate clinical performance.
  • Cleo is planning an FDA 510(k) submission in the first half of calendar year 2027, with the Clinical Validation program representing the final major clinical testing step in that pathway.

Cleo Diagnostics Limited (ASX:COV) has announced that the US laboratory infrastructure required for Clinical Validation (CV) of its Pre-Surgical Ovarian Cancer Test has been established. The company has partnered with Asuragen, the CLIA-certified US laboratory of Bio-Techne Corporation (NASDAQ:TECH), and inter-laboratory reproducibility studies are now underway. Clinical testing is expected to commence within the next month, following receipt of test kits at the laboratory.

Latest Development

Three Ella automated immunoassay instruments have been installed and commissioned at Asuragen's Facility in the United States, establishing the laboratory infrastructure needed to undertake clinical testing of Cleo's assay. Inter-laboratory reproducibility studies have begun, comparing results from Cleo's Melbourne facility with those from Asuragen, using the same Manufacturing batch. These studies are an important readiness step, ensuring that assay performance is consistent across the two laboratories before clinical testing commences.

Clinical Validation Program

The CV program will involve approximately 1,470 samples across three study populations. The first component, the Pivotal Clinical Performance Study, will use around 600 prospectively collected blood samples from Cleo's pivotal US clinical trial, conducted across 19 sites. These samples will assess the test's ability to distinguish between benign and malignant ovarian disease in women presenting with a suspicious ovarian mass. The second component, the Clinical Specificity Study, will evaluate approximately 570 samples from patients with non-ovarian benign and malignant conditions, assessing potential confounding factors. The third component, the Healthy Individuals Study, will evaluate approximately 300 samples from healthy women to establish the expected distribution of test scores in a population without known disease.

Regulatory Pathway

Clinical Validation represents the final major clinical testing program in Cleo's regulatory pathway toward an FDA 510(k) submission. The company is planning the submission for the first half of calendar year 2027. Remaining major milestones prior to submission include completion of Analytical Validation across three independently manufactured production batches, finalisation of the commercial assay algorithm, completion of CV, clinical data analysis, and the submission itself.

About CLEO's Technology

Cleo's patented technology is based on the CXCL10 biomarker, underpinned by over 15 years of scientific Research and Development at the company. CXCL10 is described as a biomarker produced early and at high levels in ovarian cancer but largely absent in benign disease, providing the basis for distinguishing malignant from non-malignant ovarian growths. Ovarian cancer has the highest five-year mortality rate of all cancers affecting women, with the majority of patients diagnosed at a late stage due to the lack of effective early detection tools. The Pre-Surgical Ovarian Cancer Test is intended to serve as a triage tool for women presenting with a suspicious ovarian mass, prior to surgery.

Company Development Stage

The company is pursuing a staged development strategy, starting with the pre-surgical triage test and planning to expand into recurrence monitoring and potentially global screening over time. The FDA 510(k) pathway for diagnostics requires demonstration of substantial equivalence to a predicate device, and the successful completion of CV is intended to form the core evidence package supporting Cleo's submission.

Sector Context

Ovarian cancer diagnostics represent an area of significant unmet medical need. Currently, no widely adopted non-invasive screening test for ovarian cancer exists. The diagnostic sector has seen growing interest in blood-based biomarker approaches, and several companies are pursuing FDA regulatory pathways for ovarian cancer detection products.

Growth Drivers

Completion of CV and the subsequent FDA 510(k) submission would represent transformative milestones for Cleo, potentially setting the company on a path toward commercial launch in the United States, the world's largest diagnostic market. A successful regulatory clearance would substantially advance the company's commercialisation prospects.

Risks and Challenges

Clinical validation programs may reveal unexpected variability in assay performance, and regulatory submissions of this nature are subject to FDA review timelines that can vary. Inter-laboratory reproducibility is critical, and any failure to demonstrate consistent performance could delay the CV program. Additionally, 510(k) submissions may require additional data or supplementary studies following FDA review.

Investor Considerations

For investors following Cleo Diagnostics, the Clinical Validation program represents the final clinical hurdle before the FDA 510(k) submission that the company has been building toward. Each milestone — Analytical Validation, CV, algorithm finalisation — reduces the execution risk in the regulatory pathway and brings the company closer to a potential commercialisation event. The United States represents the world's largest in vitro diagnostics market, and a 510(k) clearance for a blood-based ovarian cancer triage test would position Cleo to pursue commercial partnerships or direct-to-market strategies in that environment. However, the FDA review process following submission can be unpredictable in timing, and additional data requests or supplementary studies are possible. Investors should also note that competition in ovarian cancer diagnostics is evolving, with several research groups and companies pursuing related blood-based detection approaches. The company's proprietary CXCL10 biomarker and the depth of its clinical dataset — now spanning 19 US trial sites — represent meaningful differentiation.

Key Insights

Cleo Diagnostics has reached a meaningful stage in its FDA regulatory pathway with the establishment of US clinical testing infrastructure at Asuragen and the commencement of inter-laboratory reproducibility studies. The Clinical Validation program, expected to begin imminently and involving approximately 1,470 samples, is the final major clinical testing step ahead of the company's planned 510(k) submission in the first half of calendar year 2027. Progress on this pathway will be closely watched by those following developments in ovarian cancer diagnostics.